ArticleInternational journal of environmental research and public health2021

Cost-Effectiveness Analysis of Dabrafenib Plus Trametinib and Vemurafenib as First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in China.

Tianfu Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.